Canadian Online Pharmacy

Ruxolitinib

FDA approved ruxolitinib (Jakafi, Incyte Corporation) for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea (HU). December 4, 2014.  More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm425732.htm

 


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery